Works Cited

1. Schwartzberg LS. Potential practice-changing therapies in breast cancer: the year in review. Community Oncol. 2012;9(9S):540-543.

2. Brufsky MM, Dickerson SS. The diagnosis of breast cancer: transition from health to illness. Oncol Nurs Forum. 2006;33(6):1121-1127.

3. American Cancer Society. Key Statistics for Breast Cancer. Available at https://www.cancer.org/cancer/breast-cancer/about/. Last accessed July 6, 2022.

4. Baltzell K, Wrensch MR. Strengths and limitations of breast cancer risk assessment. Oncol Nurs Forum. 2005;32(3):605-616.

5. Chlebowski RT. Factors that Modify Breast Cancer Risk in Women. Available at https://www.uptodate.com/contents/factors-that-modify-breast-cancer-risk-in-women. Last accessed July 6, 2022.

6. Montgomery M. Uncertainty during breast cancer diagnostic evaluation: state of the science. Oncol Nurs Forum. 2010;37(1):77-83.

7. Lee CI, Elmore JG. Breast cancer screening. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 90-105.

8. American Cancer Society. Key Statistics for Breast Cancer in Men. Available at https://www.cancer.org/cancer/breast-cancer-in-men/about/key-statistics.html.Last accessed July 6, 2022.

9. National Cancer Institute Surveillance Epidemiology, and End Results Program. SEER Stat Fact Sheets: Female Breast Cancer. Available at https://seer.cancer.gov/statfacts/html/breast.html. Last accessed July 6, 2022.

10. American Cancer Society. Cancer Facts and Figures 2022. Atlanta: American Cancer Society; 2022.

11. Elmore JG. Screening for Breast Cancer: Strategies and Recommendations. Available at https://www.uptodate.com/contents/screening-for-breast-cancer-strategies-and-recommendations. Last accessed July 6, 2022.

12. Hutson PS. Attitudes and psychological impact of genetic testing, genetic counseling, and breast cancer risk assessment among women at increased risk. Oncol Nurs Forum. 2003;30(2):241-245.

13. Willett WC, Tamimi RM, Hankinson SE, Hazra A, Eliassen AH, Colditz GA. Nongenetic factors in the causation of breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 211-267.

14. Clark PM. Nongenetic and heritable risk factors. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 10-24.

15. Khan SA. Management of other high risk patients. In: Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 268-281.

16. Kimmick G, Seo PH, Wildiers H. Overview of the Approach to Early Breast Cancer in Older Women. Available at https://www.uptodate.com/contents/overview-of-the-approach-to-early-breast-cancer-in-older-women. Last accessed July 6, 2022.

17. Hammond MEH. Hormone Receptors in Breast Cancer: Clinical Utility and Guideline Recommendations to Improve Test Accuracy. Available at https://www.uptodate.com/contents/hormone-receptors-in-breast-cancer-clinical-utility-and-guideline-recommendations-to-improve-test-accuracy. Last accessed July 6, 2022.

18. Mahon SM. Risk factors for breast cancer. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburgh, PA: Oncology Nursing Society; 2011: 7-33.

19. American Cancer Society. Breast Cancer Risk Factors You Cannot Change. Available at https://www.cancer.org/cancer/breast-cancer/risk-and-prevention/breast-cancer-risk-factors-you-cannot-change.html. Last accessed July 6, 2022.

20. National Cancer Institute. Breast Cancer Risk in American Women. Available at https://www.cancer.gov/types/breast/risk-fact-sheet. Last accessed July 6, 2022.

21. Ooi SL, Martinez ME, Li CI. Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Res Treat. 2011;127(3):729-738.

22. Domchek SM, Peshkin BN, Schwartz MD, Isaacs C. Genetic testing and management of patients with hereditary breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 187-210.

23. National Cancer Institute. Genetics of Breast and Gynecologic Cancers (PDQ). Available at https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq. Last accessed July 6, 2022.

24. Hamilton R, Hurley K. Conditions and consequences of a BRCA mutation in young, single women of child bearing age. Oncol Nurs Forum. 2001;37(5):627-634.

25. Ashworth A. Inherited genetic factors and breast cancer. In: Harris JR, Lippmann ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 174-186.

26. Kerlikowske K, Cook A, Buist D, et al. Breast cancer risk by breast density, menopause and postmenopausal hormone therapy use.J Clin Oncol. 2010;28(24):3830-3834.

27. de Jong MM, Nolte IM, te Meerman GJ, et al. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.J Med Genet. 2002;39(4):225-242.

28. Baumann SL. Family systems genetic illness model-breast cancer. Clin J Oncol Nurs. 2006;10(3):377-381.

29. Ashcroft PF, Coleman EA, Lange U, Enderlin C, Stewart CB. Obtaining family histories from patients with cancer. Clin J Oncol Nurs. 2007;11(1):119-124.

30. Erickson J, Lyon DE. Breast cancer in Cowden syndrome: manifestation of a familial cancer syndrome. Clin J Oncol Nurs. 2010;14(1):33-35.

31. Evans DG. Li-Fraumeni Syndrome. Available at https://www.uptodate.com/contents/li-fraumeni-syndrome. Last accessed July 6, 2022.

32. Parsons M. Li-Fraumeni syndrome and the role of the pediatric nurse practitioner. Clin J Oncol Nurs. 2011;15(1):79-87.

33. Steiner E, Klubert D, Knutson D. Assessing breast cancer risk in women. Am Fam Physician. 2008;78(12):1361-1366.

34. Hayes SC, Johansson K, Stout NL, Prosnitz R, Armer JM, Gabram S, Schmitz KH. Upper-body morbidity after breast cancer incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer. 2012;18(8 Suppl):2237-2249.

35. Kessler TA. Increasing mammography and cervical cancer knowledge and screening behaviors with an educational program. Oncol Nurs Forum. 2012;39(1):61-68.

36. Cox C, Oeffinger K, Montgomery M, Hudson MM, Mertens A, Whitton J. Determinants of mammography screening participation in adult childhood cancer survivors: results from the Childhood Cancer Survivor Study. Oncol Nurs Forum. 2009;36(3):335-344.

37. Crom DB, Hinds PS, Gattuso JS, Tyc V, Hudson MM. Creating the basis for a breast health program for female survivors of Hodgkin disease using a participatory research approach. Oncol Nurs Forum. 2005;32(6):1131-1141.

38. Leahy Y. Second cancers in survivors of Hodgkin lymphoma: risks and recommendations. Clin J Oncol Nurs. 2008;12(3):437-442.

39. Jardines L, Goyal S, Royce M, Goldfarb SB. Stages 0 and I Breast Cancer. Available at https://www.cancernetwork.com/view/stages-0-and-i-breast-cancer. Last accessed July 6, 2022.

40. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353:229-237.

41. American Cancer Society. Lifestyle-Related Breast Cancer Risk Factors. Available at https://www.cancer.org/cancer/breast-cancer/risk-and-prevention/lifestyle-related-breast-cancer-risk-factors.html. Last accessed July 6, 2022.

42. Nagaiah G, Hazard HW, Abraham J. Role of obesity and exercise in breast cancer survivors. Oncol. 2010;24(4):342-345.

43. Chowdhury R, Sinha B, Sankar MJ, et al. Breastfeeding and maternal health outcomes: a systematic review and meta-analysis.Acta Paediatr. 2015;104(467):96.

44. Russell KM, Perkins SM, Zollinger TW, Champion VD. Sociocultural context of mammography screening use. Oncol Nurs Forum. 2006;33(1):105-112.

45. Vickers AJ. Prediction models in cancer care. CA Cancer J Clin. 2011;62(5):315-327.

46. Bucholtz J. Prevention strategies. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 25-44.

47. National Cancer Institute. The Breast Cancer Risk Assessment Tool. Available at https://bcrisktool.cancer.gov. Last accessed July 6, 2022.

48. Harigopal M, Singh K. Breast Development and Morphology. Available at https://www.uptodate.com/contents/breast-development-and-morphology. Last accessed July 6, 2022.

49. Yackzan SG. Pathophysiology and staging. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburg, PA: Oncology Nursing Society; 2011: 65-77.

50. Osborne MP, Boolbol SK. Breast anatomy and development. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2014: 3-14.

51. Mehrara B. Clinical Features and Diagnosis of Peripheral Lymphedema. Available at https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-peripheral-lymphedema. Last accessed July 6, 2022.

52. Muscari E. Lymphedema: responding to our patients' needs. Oncol Nurs Forum. 2004;31(5):905-912.

53. Ridner SH. Breast cancer lymphedema: pathophysiology and risk reduction guidelines. Oncol Nurs Forum. 2002;29(9):1285-1290.

54. Lawenda BD, Mondry TE, Johnstone PAS. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin. 2009;59(1):8-24.

55. Marrs J. Lymphedema and implications for oncology nursing practice. Clin J Oncol Nurs. 2007;11(1):19-21.

56. Martz CH, Kirby K. Symptom management. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburg, PA: Oncology Nursing Society; 2011: 141-117.

57. McLaughlin SA. Lymphedema. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 590-601.

58. Mahon SM. Prevention and detection. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburg, PA: Oncology Nursing Society;35-64.

59. Yarbrough SS. Older women and breast cancer screening: research synthesis. Oncol Nurs Forum. 2005;31(1):E9-E15.

60. Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev. 2003;(2):CD003373.

61. Machia J. Screening and early detection. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 45-57.

62. Bleicher RJ, Morrow M. MRI and breast cancer: role in detection, diagnosis and staging. Oncology. 2007;21(12):1521-1528.

63. Yackzan SG, Hatch J. Surgical management and reconstruction. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburg, PA: Oncology Nursing Society; 2011: 79-92.

64. U.S. Preventive Services Task Force. Breast Cancer: Screening. Available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening. Last accessed July 6, 2022.

65. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019;69(3):184-210.

66. Centers for Disease Control and Prevention. What is Breast Cancer Screening? Available at https://www.cdc.gov/cancer/breast/basic_info/screening.htm. Last accessed July 6, 2022.

67. Helvie MA, Patterson SK. Imaging analysis: mammography. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2014: 106-122.

68. Sung JS, Comstock CE. Image guided biopsy of non-palpable breast lesions. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2014: 161-173.

69. Fraker T. Diagnosis and staging. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 58-77.

70. Weinstein SP, Roth SO. Imaging analysis: magnetic resonance imaging. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 133-148.

71. Alexandraki I, Mooradian AD. Barriers related to mammography use for breast cancer screening among minority women. J Natl Med Assoc. 2010;102(3):206-218.

72. Elkin EB, Snow JG, Leoce NM, Atoria CL, Schrag D. Mammography capacity and appointment wait times: barriers to breast cancer screening. Cancer Causes Control. 2012;23(1):45-50.

73. Robertson FM, Bondy M, Yang W, et al. Inflammatory breast cancer the disease, the biology, the treatment. CA Cancer J Clin. 2010;60(6):351-376.

74. U.S. Preventive Services Task Force. BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing. Available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing. Last accessed July 6, 2022.

75. Allred DC. Pathology and biological features of premalignant breast disease. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 4th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2010: 321-332.

76. Sabel MS. Overview of Benign Breast Disease. Available at https://www.uptodate.com/contents/overview-of-benign-breast-disease. Last accessed July 6, 2022.

77. American Cancer Society. Non-Cancerous Breast Conditions. Available at https://www.cancer.org/cancer/breast-cancer/non-cancerous-breast-conditions.html. Last accessed July 6, 2022.

78. Winkeljohn DL. Triple-negative breast cancer. Clin J Oncol Nurs. 2008;12(6):861-863.

79. Morrow M. Physical examination of the breast. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams &Wilkins; 2014: 25-28.

80. Pineault P. Breast cancer screening: women's experiences of waiting for further testing. Oncol Nurs Forum. 2007;34(4):847-853.

81. Solin LJ. Breast conservation treatment with radiation: an ongoing success story. J Clin Oncol. 2010;28(5):709-711.

82. Burstein H. Selection and Administration of Adjuvant Chemotherapy for HER2-Negative Breast Cancer. Available at https://www.uptodate.com/contents/selection-and-administration-of-adjuvant-chemotherapy-for-her2-negative-breast-cancer.adjuvant-chemotherapy-for-her2-negative-breast-cancer. Last accessed July 6, 2022.

83. Pritchard KI. Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer. Available at https://www.uptodate.com/contents/adjuvant-endocrine-therapy-for-non-metastatic-hormone-receptor-positive-breast-cancer. Last accessed July 6, 2022.

84. Maxwell C. Biomarker research in breast cancer. Clin J Oncol Nurs. 2010;149(6):771-783.

85. Loerzel VW, Hassey DK. Male breast cancer. Clin J Oncol Nurs. 2004;8(2):191-192.

86. Sedgwick EL. Imaging analysis: ultrasound. In: Harris JR, Lippmann ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 123-132.

87. Cancer Treatment Centers of America. Biopsy. Available at https://www.cancercenter.com/diagnosing-cancer/diagnostic-procedures/biopsy. Last accessed July 6, 2022.

88. Hassey DK. Targeted therapy and treatment of recurrent and metastatic breast cancer. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2003: 163-174.

89. American Cancer Society. Breast Biopsy: Types of Biopsy Procedures. Available at https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/breast-biopsy.html. Last accessed July 6, 2022.

90. Bleicher RJ. Management of the palpable breast mass. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2014: 29-37.

91. Lucas JH, Cone L. Breast cyst aspiration. Am Fam Physician. 2003;68(10):1983-1987.

92. MedlinePlus. Breast Biopsy: Stereotactic. Available at https://www.nlm.nih.gov/medlineplus/ency/article/007433.htm. Last accessed July 6, 2022.

93. Collins LC, Laronga C, Wong JS. Breast Ductal Carcinoma In Situ: Epidemiology, Clinical Manifestations, and Diagnosis. Available at https://www.uptodate.com/contents/breast-ductal-carcinoma-in-situ-epidemiology-clinical-manifestations-and-diagnosis. Last accessed July 6, 2022.

94. Chung AP, Giuliano AE. Sentinel lymph node biopsy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 553-569.

95. Harlow SD, Weaver DL. Overview of Sentinel Lymph Node Biopsy in Breast Cancer. Available at https://www.uptodate.com/contents/overview-of-sentinel-lymph-node-biopsy-in-breast-cancer. Last accessed July 6, 2022.

96. Cody HS, Putas G. Axillary dissection. In: Harris JRE, Lippman M, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 570-578.

97. Bleiweiss IJ. Pathology of Breast Cancer. Available at https://www.uptodate.com/contents/pathology-of-breast-cancer. Last accessed July 6, 2022.

98. Sabel MS, Collins LC. Atypia and Lobular Carcinoma In Situ: High Risk Lesions of the Breast. Available at https://www.uptodate.com/contents/atypia-and-lobular-carcinoma-in-situ-high-risk-lesions-of-the-breast. Last accessed July 6, 2022.

99. Murray L, Reintgen M, Akman K, et al. Pleomorphic lobular carcinoma in situ: treatment options for a new pathologic entity.Clin Breast Cancer. 2012;12(1):76-79.

100. National Breast Cancer Foundation, Inc. Invasive Ductal Carcinoma (IDC). Available at https://www.nationalbreastcancer.org/invasive-ductal-carcinoma. Last accessed July 6, 2022.

101. Harvey JA. Unusual breast cancers: useful clues to expanding the differential diagnosis. Radiology. 2007;242(3):683-694.

102. Taghian A, Merajver SD. Inflammatory Breast Cancer: Clinical Features and Treatment. Available at https://https://www.medilib.ir/uptodate/show/768. Last accessed July 6, 2022.

103. Amin MB, Edge SB, Greene FL, et al (eds). AJCC Cancer Staging Handbook. 8th ed. New York, NY: Springer; 2017.

104. National Breast Cancer Foundation, Inc. Inflammatory Breast Cancer. Available at https://www.nationalbreastcancer.org/inflammatory-breast-cancer. Last accessed July 6, 2022.

105. Sabel MS, Weaver DL. Paget Disease of the Breast. Available at https://www.uptodate.com/contents/paget-disease-of-the-breast. Last accessed July 6, 2022.

106. Cleere DW. Triple-negative breast cancer: a clinical update. Commun Oncol. 2010;7(5):203-211.

107. Eisenberg S. Systemic therapy. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburgh, PA: Oncology Nursing Society; 2011: 113-140.

108. Hawk N, O'Regan R. Treatment of triple-negative breast cancer. Community Oncol. 2010;7(7):328-332.

109. Schwartzberg LS. New directions in the treatment of triple-negative breast cancer. Community Oncol. 2010;7(5):7-10.

110. Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28:2114-2122.

111. National Breast Cancer Foundation, Inc. Triple Negative Breast Cancer. Available at https://www.nationalbreastcancer.org/triple-negative-breast-cancer. Last accessed July 6, 2022.

112. Press MF, Ma Y. HER2/ERBB2 testing: assessment of status for targeted therapies. In: Harris J, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 423-438.

113. Schiff R, Osborne CK, Fuqua SAW. Clinical aspects of estrogen and progesterone receptors. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 4th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001: 408-430.

114. Chorn N. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy. Oncol Nurs Forum. 2006;33(2):265-272.

115. American Joint Committee on Cancer. Cancer Staging Systems: What is Cancer Staging? Available at https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/cancer-staging-systems/. Last accessed July 6, 2022.

116. American Joint Committee on Cancer. AJCC Eighth Edition Update to Breast Chapter. Available at https://cancerstaging.us10.list-manage.com/subscribe?u=e4fcf2de02afbcaa9a2820fea&id=08450ea96e. Last accessed July 6, 2022.

117. Genestie C, Zafrani B, Asselain B, et al. Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems. Anticancer Res. 1998;18(1B):571-576.

118. Morrow M, Golshan M. Mastectomy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 504-509.

119. Kwong A, Sable MS. Mastectomy. Available at https://www.uptodate.com/contents/mastectomy-indications-types-and-concurrent-axillary-lymph-node-management. Last accessed July 6, 2022.

120. Nahabedian M. Overview of Breast Reconstruction. Available at https://www.uptodate.com/contents/overview-of-breast-reconstruction. Last accessed July 6, 2022.

121. Sabel MS. Breast Conserving Therapy. Available at https://www.uptodate.com/contents/breast-conserving-therapy. Last accessed July 6, 2022.

122. Lynn J. Surgery techniques. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 81-89.

123. Nissen MJ, Swenson K, Kind EA. Quality of life after post mastectomy breast reconstruction. Oncol Nurs Forum. 2002;29(30):547-553.

124. Hill O, White K. Exploring women's experiences of TRAM flap breast reconstruction after mastectomy for breast cancer. Oncol Nurs Forum. 2008;35(1):81-88.

125. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-1241.

126. van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92(14):1143-1150.

127. Blichert-Toft M, Nielsen M, Düring M, et al. Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol. 2008;47(4):672-681.

128. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227-1232.

129. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trials. N Engl J Med. 1995;333:1444-1455.

130. Jatoi I, Proschan MA. Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results. Am J Clin Oncol. 2005;28(3):289-294.

131. van der Hage JA, Putter H, Bonnema J, et al. Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis. Eur J Cancer. 2003;39(15):2192-2199.

132. Buchholz TA, Hunt KK. Breast-conserving therapy: conventional whole breast irradiation. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2010: 507-521.

133. Perun J. Radiation therapy. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 110-133.

134. Jancin B. Brachytherapy doubles the risk of breast loss. Community Oncol. 2011;8(12):549-550.

135. Jenkins RW, Cannick L III, Harper JL. Use of MammoSite balloon brachytherapy for early-stage breast cancer. Community Oncol. 2011;8(1):37-40.

136. Mehrara BJ, Ho AY. Breast reconstruction. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 536-552.

137. National Comprehensive Cancer Network. NCCN Breast Cancer Guideline V.4.2022. Available at https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Last accessed July 6, 2022.

138. Baron R, Vaziri N. Reconstructive surgery. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 90-109.

139. Shockney DL, Tsangaris TT (eds). The Johns Hopkins Breast Cancer Handbook for Health Care Professionals. Boston, MA: Jones and Bartlett; 2008.

140. Shen J. Implications of post-mastectomy radiation therapy on optimal timing and approach for breast reconstruction. Community Oncol. 2010;7(12):548-560.

141. Dell DD, Weaver C, Kozempel J, Barsevick A. Recovery after transverse rectus abdominis myocutaneous flap breast construction surgery. Oncol Nurs Forum. 2008;35(2):189-196.

142. Stephens PA, Osowski M, Fidale MS, Spagnoli C. Identifying the educational needs and concerns of newly diagnosed patients with breast cancer after surgery. Clin J Oncol Nurs. 2008;12(2):253-258.

143. Johns Hopkins Medicine. Breast Reconstruction: Autologous Tissue Surgery: Transverse Rectus Abdominis Myocutaneous (TRAM) Flap. Available at https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/breast-reconstruction. Last accessed July 6, 2022.

144. Zenn MR. Free TRAM Breast Reconstruction. Available at https://emedicine.medscape.com/article/1273997-overview. Last accessed July 6, 2022.

145. Kim JYS. Latissimus Flap Breast Reconstruction. Available at https://emedicine.medscape.com/article/1274087-overview. Last accessed July 6, 2022.

146. Casey MA, Mahon SM. Breast restoration options utilizing prostheses. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburg, PA: Oncology Nursing Society; 2011: 93-103.

147. American Cancer Society. Reach To Recovery. Available at https://www.cancer.org/involved/volunteer/reach-to-recovery.html. Last accessed July 6, 2022.

148. Kenefick AL. Patterns of symptom distress in older women after surgical treatment for breast cancer. Oncol Nurs J. 2006;33(2):327-335.

149. Ridner SH, Dietrich MS. Self-reported comorbid conditions and medication usage in breast cancer survivors with and without lymphedema. Oncol Nurs Forum. 2008;35(1):57-63.

150. Armer J. Lymphedema. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 209-229.

151. Singer M. Lymphedema in breast cancer: dilemmas and challenges. Clin J Oncol Nurs. 2009;13(3):350-352.

152. McLaughlin SM, Wright MJ, Morris KT, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008;26(32):5213-5219.

153. Poage E, Singer M, Armer J, Poundall M, Shellabarger JM. Demystifying lymphedema: development of the lymphedema putting evidence into practice card. Clin J Oncol Nurs. 2008;12(6):951-964.

154. Radina ML, Armer JM, Culbertson SD, Dusold JM. Post-breast cancer lymphedema: understanding women's knowledge of their condition. Oncol Nurs Forum. 2004;31(1):97-104.

155. National Comprehensive Cancer Network. NCCN Guidelines Version 1.2022 Survivorship: Lymphedema. Available at https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf. Last accessed July 6, 2022.

156. Asdourian MS, Skolny MN, Brunelle C, et al. Precautions for breast cancer-related lymphoedema: risk from air travel, ipsilateral arm blood pressure measurements, skin puncture, extreme temperatures, and cellulitis. Lancet Oncol. 2016;17:e392-e405.

157. Ahn S, Port ER. Lymphedema precautions: time to abandon old practices? J Clin Oncol. 2016;34:655-658.

158. National Cancer Institute. Lymphedema (PDQ) – Health Professional Version. Available at https://www.cancer.gov/about-cancer/treatment/side-effects/lymphedema/lymphedema-hp-pdq. last accessed July 6, 2022.

159. Mehrara B. Clinical Staging and Conservative Management of Peripheral Lymphedema. Available at https://www.uptodate.com/contents/clinical-staging-and-conservative-management-of-peripheral-lymphedema. Last accessed July 6, 2022.

160. Ferraro CJ, Catanzaro PJ. Radiation therapy. In: Mahon SM (ed). Breast Cancer. 2nd ed. Pittsburg, PA: Oncology Nursing Society; 2011: 105-111.

161. Camporeale J. Basics of radiation treatment. Clin J Oncol Nurs. 2008;12(2):193-195.

162. Gordils-Perez J, Rawlins-Duell R, Kelvin JF. Advances in radiation treatment of patients with breast cancer. Clin J Oncol Nurs. 2003;7(6):629-636.

163. Sabel MS. Breast Conserving Therapy. Available at https://www.uptodate.com/contents/breast-conserving-therapy. Last accessed July 6, 2022.

164. Tann AW, Hatch SS, Joyner MM, Wiederhold LR, Swanson TA. Accelerated partial breast irradiation: past, present, and future. World J Clin Oncol. 2016;7(5):370-379.

165. Hogel WP, Quinn AE, Heron DE. Advances in brachytherapy: new approaches to target breast cancer. Clin J Oncol Nurs. 2003;7(3):324-328.

166. Harris JR, Morrow M. Breast-conserving therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2014: 514-535.

167. Correa C, Harris EE, Leonardi MC, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. ASTRO. 2017;7(2):73-79.

168. The American Society of Breast Surgeons. Consensus Guideline on Accelerated Partial Breast Irradiation. Available at https://www.breastsurgeons.org/docs/statements/Consensus-Statement-for-Accelerated-Partial-Breast-Irradiation.pdf. Last accessed July 6, 2022.

169. Poirier P. The relationship of sick leave benefits, employment patterns, and individual characteristics of radiation therapy-related fatigue. Oncol Nurs Forum. 2006;33(3):593-601.

170. Iwamoto RR, Haas ML, Gosselin-Acomb T (eds). Manual for Radiation Oncology Nursing Practice and Education. 4th ed. Pittsburgh, PA: Oncology Nursing Society; 2012.

171. Escalante CP. Cancer-Related Fatigue: Prevalence, Screening and Clinical Assessment. Available at https://www.uptodate.com/contents/cancer-related-fatigue-prevalence-screening-and-clinical-assessment. Last accessed July 6, 2022.

172. Aistars J. The validity of skin care protocols followed by women with breast cancer receiving external radiation. Clin J Oncol Nurs. 2006;10(4):487-492.

173. Gosselin T, Schneider SM, Plambeck MA, Rowe K. A prospective randomized, placebo-controlled skin care study in women diagnosed with breast cancer undergoing radiation therapy. Oncol Nurs Forum. 2010;37(5):619-626.

174. Deutsch M, Flickinger JC. Compliance with adjuvant radiotherapy after surgery for primary breast cancer. Community Oncol. 2009;6(12):547-550.

175. Geddie P. Adjuvant therapy. In: Hassey DK (ed.). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 134-145.

176. U.S. Preventive Services Task Force. Breast Cancer: Medication Use to Reduce Risk. Available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction. Last accessed July 6, 2022.

177. Sharma P. Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Prevention. Available at https://www.uptodate.com/contents/selective-estrogen-receptor-modulators-and-aromatase-inhibitors-for-breast-cancer-prevention. Last accessed July 6, 2022.

178. Lexicomp Online. Available at https://online.lexi.com. Last accessed July 6, 2022.

179. BreastCancer.org. Fareston. Available at https://www.breastcancer.org/treatment/hormonal-therapy/fareston. Last accessed July 6, 2022.

180. Kohli M, Lawrence TS, Reddy NM, et al. Principles of antineoplastic therapy. In: Rose M, DeVitaVT Jr, Lawrence TS, Wender RC (eds). Oncology in Primary Care. Philadelphia, PA: Lippincott Williams & Wilkins; 2013.

181. Geddie P. Acute side effect management. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 189-197.

182. Versea L, Rosenzweig M. Hormonal therapy for breast cancer: focus on fulvestrant. Clin J Oncol Nurs. 2003;7(3):307-311.

183. Savage MI, Brown PH. Chemoprevention. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 282-308.

184. Rae JM. Pharmacogenomics of systemic therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 693-699.

185. Kuderer NM, Peppercorn J. CYP2D6 testing in breast cancer: ready for prime time? Oncology. 2009;23(14):1223-1232.

186. Harwood KV. Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life. Clin J Oncol Nurs. 2004;8(6):629-637.

187. Rimawi MF, Osborne CK. Adjuvant systemic therapy: endocrine therapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 618-634.

188. Moore S. Nonadherence in patients with breast cancer receiving oral therapies. Clin J Oncol. 2010;14(1):41-47.

189. Litsas G. Nursing perspectives on fulvestarant for the treatment of postmenopausal women with metastatic breast cancer. Clin J Oncol Nurs. 2011;15(6):674-681.

190. U.S. Food and Drug Administration. News Release: FDA Approves First PI3K Inhibitor for Breast Cancer. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-pi3k-inhibitor-breast-cancer. Last accessed July 6, 2022.

191. Dienger MJ. Hormonal therapy. In: Hassey DK (ed). Contemporary Issues in Breast Cancer. 2nd ed. Boston, MA: Jones and Bartlett; 2004: 146-159.

192. Winters L, Habin K, Gallagher J. Aromatase inhibitors and musculoskeletal pain in patients with breast cancer. Clin J Oncol Nurs. 2007;11(3):433-439.

193. Gradishar WJ, Ruddy KJ. Breast Cancer in Men. Available at https://www.uptodate.com/contents/breast-cancer-in-men. Last accessed July 6, 2022.

194. Listas G. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence. Oncol Nurs Forum. 2008;35(4):714-721.

195. Palmieri FM, Frye DK, Mahon SM. Current clinical issues in systemic therapy for metastatic breast cancer. Clin J Oncol Nurs. 2009;14(3):4-10.

196. Schott AF. Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. Available at https://www.uptodate.com/contents/chemotherapy-in-patients-with-hormone-receptor-positive-her2-negative-advanced-breast-cancer. Last accessed July 6, 2022.

197. Arteaga CL. Tyrosine kinase inhibitors. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2010: 960-970.

198. Sheth S, Pal SK, Pegan MD. Treatment of HER2-overexpressing metastatic breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 960-973.

199. Tan SH, Wolff AC. Treatment of metastatic breast cancer: chemotherapy. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 929-959.

200. Dall P, Lenzen G, Göhler T, et al. Trastuzumab in the treatment of elderly patients with early breast cancer: results from an observational study in Germany. Geriatr Oncol. 2015;6(6):462-469.

201. Zucchini G, Bernardi A, Martoni A, Zamagni. Tolerability and activity of trastuzumab in elderly patients with HER2-overexpressing metastatic breast cancer. Ann Oncol. 2013;24(1):264-265.

202. Albanell J, Ciruelos EM, Lluch A, Muñoz M, Rodriguez CA. Trastuzumab in small tumours and in elderly women. Cancer Treat Rev. 2014;40(1):41-47.

203. U.S. Food and Drug Administration. Archive: FDA Approves New Treatment for Late-Stage Breast Cancer. Available at https://wayback.archive-it.org/7993/20170112023904/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340704.htm. Last accessed July 6, 2022.

204. Abraham J. Novel HER2-targeted agents for breast cancer therapy. Community Oncol. 2011;8(8):1-3.

205. U.S. Food and Drug Administration. Archive: FDA Approves Perjeta for Neoadjuvant Breast Cancer Treatment: First Drug Approved for Use in Preoperative Breast Cancer. Available at https://wayback.archive-it.org/7993/20170111161055/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370393.htm. Last accessed July 6, 2022.

206. U.S. Food and Drug Administration. FDA Approves Atezolizumab for PD-L1 Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer. Available at https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative. Last accessed July 6, 2022.

207. U.S. Food and Drug Administration. FDA Approves New Treatment Option for Patients with HER2-Positive Breast Cancer Who Have Progressed on Available Therapies. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available. Last accessed July 6, 2022.

208. U.S. Food and Drug Administration. FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-triple-negative-breast-cancer-has-spread-not-responded-other-treatments. Last accessed July 6, 2022.

209. Mittra A, Tripathy D. Looking ahead to rational combinational therapy. Community Oncol. 2012;9(2):40-44.

210. Murphy CG, Fortnier M. HER-2 positive breast cancer: beyond trastuzumab. Oncol. 2010;24(5):410-415.

211. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013;14(1):64-71.

212. Winkeljohn DL. Adherence to oral cancer therapies: nursing interventions. Clin J Oncol Nurs. 2010;14(4):461-466.

213. U.S. Food and Drug Administration. Archive: FDA Approves Ibrance for Postmenopausal Women with Advanced Breast Cancer. Available at https://wayback.archive-it.org/7993/20170722173035/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432871.htm. Last accessed July 6, 2022.

214. Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38(31):3698-3715.

215. Hurtig J. Managing patients with advanced and metastatic breast cancer. Clin J Oncol Nurs. 2010;14(3):313-323.

216. Dang C, Hudis CA. Adjuvant systemic chemotherapy in early breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds). Diseases of the Breast. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2014: 635-648.

217. Taylor CW, Muss HB. Adjuvant chemotherapy of breast cancer in the older patient. Oncology. 2010;24(7):608-613.

218. Chu E, DeVita VT. Physicians' Cancer Chemotherapy Drug Manual. 19th ed. Boston, MA: Jones & Bartlett; 2019.

219. Drugs@FDA. Label and Approval History: Doxorubicin Hydrochloride. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050629s022lbl.pdf. Last accessed July 6, 2022.

220. Palmieri FM, Myatt CV, Perez EA. Adjuvant trastuzumab for HER-2 positive early breast cancer: a review of clinical data with nursing implications. Clin J Oncol Nurs. 2010;14(3):326-336.

221. Frye D. Capecitabine-based combination therapy for breast cancer: implications for nurses. Oncol Nurs Forum. 2009;36(10):105-113.

222. U.S. Food and Drug Administration. FDA Approves First Treatment for Breast Cancer with a Certain Inherited Genetic Mutation. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-breast-cancer-certain-inherited-genetic-mutation. Last accessed July 6, 2022.

223. U.S. Food and Drug Administration. FDA Approves Talazoparib for gBRCAm HER2-Negative Locally Advanced or Metastatic Breast Cancer. Available at https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-gbrcam-her2-negative-locally-advanced-or-metastatic-breast-cancer. Last accessed July 6, 2022.

224. Hawkins R, Grunberg S. Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved outcomes. Clin J Oncol Nurs. 2009;13(1):54-64.

225. Polovich M, Olsen M, LeFebvre K (eds). Chemotherapy and Biotherapy Guidelines and Recommendations for Practice. 4th ed. Pittsburgh, PA: Oncology Nursing Society; 2014.

226. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update.J Clin Oncol. 2017;35(28):3240-3261.

227. Donovan D. Management of peripheral neuropathy caused by microtubule inhibitors. Clin J Oncol Nurs. 2009;13(6):686-694.

228. Wickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clin J Oncol Nurs. 2007;11(3):361-376.

229. Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer. 2011;19(10):1647-1656.

230. Whittaker AL, George RP, O'Malley L. Prevalence of cognitive impairment following chemotherapy treatment for breast cancer: a systematic review and meta-analysis. Sci Rep. 2022;12:2135.

231. Myers JS. Chemotherapy-related cognitive impairment: the breast cancer experience. Oncol Nurs Forum. 2012;39(1):E31-E40.

232. Nelson CJ, Nandy N, Roth AJ. Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliat Support Care. 2007;5(3):273-280.

233. Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30(3):274-281.

234. Brem S, Kumar NB. Management of treatment-related symptoms in patients with breast cancer: current strategies and future directions. Clin J Oncol Nurs. 2011;15(1):63-71.

235. Evens K, Eschiti VS. Cognitive effects of cancer treatment: "chemo brain" explained. Clin J Oncol Nurs. 2009;13(6):661-666.

236. Staat K, Segatore M. The phenomenon of chemo brain. Clin J Oncol Nurs. 2005;9(6):713-721.

237. Schilder CM, Seynaeve C, Linn SC, et al. Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. Crit Rev Oncol Hematol. 2010;76(2):133-141.

238. Biglia N, Bounous VE, Malabaila A, et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care. 2012;21(4):485-492.

239. Selamat MH, Loh SY, Mackenzie L, Vardy J. Chemobrain experienced by breast cancer survivors: a meta-ethnography study investigating research and care implications. PLoS One. 2014;9(9):E108002.

240. Asher A. Cognitive dysfunction among cancer survivors. Am J Phys Med Rehabil. 2011;90:16-26.

241. Von Ah D, Habermann B, Carpenter JS, Schneider BL. Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs. 2013;17:236-241.

242. Munir F, Burrows J, Yarker J, Kalawsky K, Bains M. Women's perceptions of chemotherapy-induced cognitive side effects on work ability: a focus group study. J Clin Nurs. 2010;19(9-10):1362-1370.

243. Boykoff N, Moieni M, Subramaniam SK. Confronting chemobrain: an in depth look at survivors' reports of impact on work, social network, and health care response. J Cancer Survivor. 2009;3(4):223-232.

244. Hurter B, Bush NJ. Cancer-related anemia. Clin J Oncol Nurs. 2007;11(3):349-359.

245. Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev. 2010;(7):CD006704.

246. Radbruch L, Strasser F, Elsner F, et al. Fatigue in palliative care patients—an EAPC approach. Palliat Med. 2008;22(1):13-32.

247. U.S. Food and Drug Administration. Drug Approvals and Database. Available at https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases. Last accessed July 6, 2022.

248. Fuerst M. Relieving cancer-related fatigue: medication, exercise, and psychosocial interventions. Oncol Times. 2010;32(15):26-29.

249. Gelinas C, Fillion L. Factors related to persistent fatigue following completion of breast cancer treatment. Oncol Nurs Forum. 2004;31(2):269-278.

250. National Comprehensive Cancer Network. NCCN Cancer-Related Fatigue: Guideline V.2.2022. Available at https://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf. Last accessed July 6, 2022.

251. Harris J. Fatigue in chronically ill patients. Curr Opin Support Palliat Care. 2008;2(3):180-186.

252. Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2008;(2):CD006145.

253. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2012;11:CD006145.

254. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33.

255. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer. 2004;101(1):51-57.

256. Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist. 2005;10(7):471-479.

257. National Cancer Institute. Male Breast Cancer Treatment (PDQ). Available at https://www.cancer.gov/types/breast/hp/male-breast-treatment-pdq.breast-treatment-pdq. Last accessed July 6, 2022.

258. Ravi A, Bang H, Karsif K, Nori D. Breast cancer in men: prognostic factors, treatment patterns, and outcome. Am J Men's Health. 2012;6:51-58.

259. Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer. 1999;85(3):629-639.

260. Cimmino VM, Degnim AC, Sabel MS, et al. Efficacy of sentinel lymph node biopsy in male breast cancer. J Surg Oncol. 2004;86(2):74-77.

261. Goyal A, Horgan K, Kissin M, et al. Sentinel lymph node biopsy in male breast cancer patients. Eur J Surg Oncol. 2004;30(5):480-483.

262. Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer. 1992;65(2):252-254.

263. Wernberg JA, Yap J, Murekeyisoni C, et al. Multiple primary tumors in men with breast cancer diagnoses—a SEER database review. J Surg Oncol. 2009;99:16-19.

264. U.S. Food and Drug Administration. FDA Approves First Targeted Therapy for HER2-Low Breast Cancer. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-her2-low-breast-cancer. Last accessed November 15, 2022.

Evidence-Based Practice Recommendations Citations

1. Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(7):961-965. Available at https://ascopubs.org/doi/full/10.1200/JCO.2012.45.9859. Last accessed July 21, 2022.

2. American College of Obstetricians and Gynecologists. Breast Cancer Risk Assessment and Screening in Average-Risk Women. Washington, DC: American College of Obstetricians and Gynecologists; 2017. Reaffirmed 2021. Available at https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2017/07/breast-cancer-risk-assessment-and-screening-in-average-risk-women. Last accessed July 21, 2022.

3. Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2021;39(35):3959-3977. Available at https://ascopubs.org/doi/full/10.1200/JCO.21.01392. Last accessed July 21, 2022.

4. Visvanathan K, Fabian CJ, Bantug E, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol. 2019;37(33):3152-3165. Available at https://ascopubs.org/doi/full/10.1200/JCO.19.01472. Last accessed July 21, 2022.

5. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(28):3240-3261. Available at https://ascopubs.org/doi/10.1200/JCO.2017.74.4789. Last accessed July 21, 2022.


Copyright © 2022 NetCE, PO Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.